Skip to main content
Subscribe
Log In
More
Log in via Institution
Log in via OpenAthens
Log in via your Society
Select your society
ESGO
IGCS
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Current issue
Archive
Authors
About
YouTube
Podcasts
Zoom Journal Club
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Current issue
Archive
Authors
About
YouTube
Podcasts
Zoom Journal Club
Subscribe
Log in
More
Log in via Institution
Log in via OpenAthens
Log in via your Society
Select your society
ESGO
IGCS
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
Archive
Volume 31, Issue Suppl 3
1195 Results of NSGO-OV-UMB1/ENGOT-OV30 study: a phase II study of durvalumab and oleclumab in patients with relapsed ovarian cancer (OC)
Email alerts
Article metrics
Article menu
Article
Text
Article
info
Citation
Tools
Share
Rapid Responses
Article
metrics
Alerts
PDF
Late breaking abstracts
Ovarian cancer
1195 Results of NSGO-OV-UMB1/ENGOT-OV30 study: a phase II study of durvalumab and oleclumab in patients with relapsed ovarian cancer (OC)
Free
Online download statistics by month:
Online download statistics by month: October 2021 to March 2024
Abstract
Full
Pdf
Oct 2021
32
0
11
Nov 2021
68
0
9
Dec 2021
77
0
13
Jan 2022
133
0
9
Feb 2022
69
0
13
Mar 2022
90
0
14
Apr 2022
74
0
17
May 2022
73
0
23
Jun 2022
95
0
22
Jul 2022
69
0
21
Aug 2022
55
0
13
Sep 2022
128
0
11
Oct 2022
66
0
15
Nov 2022
38
0
7
Dec 2022
49
0
7
Jan 2023
85
0
14
Feb 2023
53
0
4
Mar 2023
45
0
5
Apr 2023
53
0
14
May 2023
46
0
6
Jun 2023
27
0
12
Jul 2023
23
0
6
Aug 2023
45
0
3
Sep 2023
26
0
4
Oct 2023
83
0
5
Nov 2023
49
0
6
Dec 2023
35
0
5
Jan 2024
17
0
3
Feb 2024
21
0
3
Mar 2024
13
0
5
Total
1737
0
300
Read the full text or download the PDF:
Subscribe
Log in
Log in via Institution
Log in via OpenAthens
Log in via your Society
Select your society
ESGO
IGCS
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?